Dopamine D1 Agonists: First Potential Treatment for Late-Stage Parkinson’s Disease is a research paper published in Biomolecules (2023). On theSindex it has a DataRank of 0. It has been cited 16 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Pfizer
Grant: R01 NS060722
Pfizer
Grant: U01 NS082151
Pfizer
Grant: R01 MH040537
Pfizer
Grant: R01 NS105471
Pfizer
Grant: R01 AG071675
Pfizer
Grant: R21 NR017259
Pfizer
Grant: R00 AG056670
Pfizer
Grant: UL1 TR002014
NIH HHS
Grant: NR017259
NIH HHS
Grant: MH040537
NIH HHS
Grant: NS060722
NIA NIH HHS
Grant: RF1 AG071675
NIH HHS
Grant: AG056670
NIH HHS
Grant: NS082151
NIH HHS
Grant: NS112008
NIH HHS
Grant: TR002014
National Institutes of Health
Grant: 5R00AG056670-05
Self-regulation of Health Promotion: the Roles of Momentary Variability in Working Memory Capacity and Neurocognitive Aging
National Institutes of Health
Grant: 4R01AG071675-02
Discovery of functionally selective dopamine ligands for age-related cognitive decline
National Institutes of Health
Grant: 5R01NS060722-03
Structural MRI marker(s) of Parkinson's Disease's Progression
National Institutes of Health
Grant: 2UL1TR002014-05A1
Penn State Clinical and Translational Science Institute
National Institutes of Health
Grant: 5R01NS105471-02
In vivo agonist molecular probes for the dopamine D1 receptor
National Institutes of Health
Grant: 5R01MH040537-04
NOVEL MOLECULAR SITE FOR ANTIDOPAMINERGIC EFFECTS
National Institutes of Health
Grant: 5U01NS082151-03
Multimodal MRI markers of nigrostriatal pathology in Parkinson's disease
National Institutes of Health
Grant: 1R21NR017259-01
Communication quality analysis of end-of-life discussions by clinicians
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals